Alembic Pharmaceuticals balance sheet

As of Mar 2026

Total assets: ₹8,763cr+12.7% on Mar 2025
Shareholders' equity: ₹5,669cr+9.2% on Mar 2025
Total debt: ₹1,361cr+13.8% on Mar 2025
Cash and investments: ₹196cr+135.2% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	2,844	2,524	2,547	2,398
	634	837	524	601
	237	0.0	0.0	0.0
	49.7	0.0	0.0	0.0
	27.7	25.7	24.4	25.1
	113	101	68.6	71.2
	113	101	68.6	71.2
	270	166	170	123
	15.4	31.2	33.3	53.7
	4,190	3,685	3,367	3,273
	2,511	2,288	1,644	1,475
	1,466	1,400	1,025	1,046
	196	83.5	120	75.5
	6.3	6.6	6.4	6.8
	13.9	11.5	20.8	9.8
	1,683	1,501	1,172	1,139
	338	287	222	214
	4,543	4,088	3,079	2,910
	30.0	0.0	0.0	0.0
	8,763	7,773	6,446	6,183
Equity
	39.3	39.3	39.3	39.3
	5,636	5,152	4,779	4,331
	5,675	5,191	4,818	4,370
	−5.8	−1.4	0.0	0.0
	5,669	5,190	4,818	4,370
Liabilities
	122	0.0	0.0	0.0
	44.8	46.8	62.9	69.2
	167	46.8	62.9	69.2
	153	124	110	106
	180	0.0	0.0	0.0
	500	171	172	175
	1,239	1,196	430	636
	835	880	736	680
	303	165	164	166
	2,377	2,241	1,330	1,481
	111	85.9	65.3	70.1
	35.0	18.9	0.0	0.0
	70.8	66.8	60.0	85.5
	2,594	2,412	1,455	1,637
	3,094	2,583	1,627	1,812
	8,763	7,773	6,446	6,183
Assets — additional as-filed lines
	10.7	11.0	41.0	82.7
Trade payables — MSME split
	59.8	60.3	—	—
	775	820	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹764.90

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,034 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	2,398.5	2,546.7	2,523.5	2,843.6	2,843.6
+ Capital Work-in-Progress	601.3	524.4	837.2	633.7	633.7
+ Other Intangibles	0.0	0.0	0.0	237.1	237.1
+ Intangibles under Development	0.0	0.0	0.0	49.7	49.7
+ Investments (Equity Method)	25.1	24.4	25.7	27.7	27.7
+ Non-current Investments	71.2	68.6	101.5	113.2	113.2
Non-current Financial Assets	71.2	68.6	101.5	113.2	113.2
+ Deferred Tax Assets	123.0	169.6	166.0	269.6	269.6
+ Other Non-current Assets	53.7	33.3	31.2	15.4	15.4
Total Non-current Assets	3,272.8	3,367.0	3,685.1	4,190.0	4,190.0
Current Assets
+ Inventories	1,475.3	1,643.5	2,288.1	2,510.6	2,510.6
+ Trade Receivables	1,046.4	1,024.8	1,399.8	1,466.3	1,466.3
+ Cash & Cash Equivalents	75.5	120.2	83.5	196.4	196.4
+ Other Bank Balances	6.8	6.4	6.6	6.3	6.3
+ Other Current Financial Assets	9.8	20.8	11.5	13.9	13.9
Current Financial Assets	1,138.5	1,172.2	1,501.4	1,682.9	1,682.9
+ Other Current Assets	213.5	221.8	287.2	338.4	338.4
Total Current Assets	2,910.0	3,078.6	4,087.8	4,542.6	4,542.6
+ Assets Held for Sale	0.0	0.0	0.0	30.0	30.0
Total Assets	6,182.8	6,445.6	7,772.9	8,762.6	8,762.6
Equity
+ Equity Share Capital	39.3	39.3	39.3	39.3	39.3
+ Other Equity / Reserves	4,331.2	4,778.9	5,151.6	5,635.5	5,635.5
Equity — Owners of Parent	4,370.5	4,818.2	5,190.9	5,674.8	5,674.8
+ Minority Interest	0.0	0.0	-1.4	-5.8	-5.8
Total Equity	4,370.5	4,818.2	5,189.5	5,669.0	5,669.0
Liabilities
+ Borrowings — Non-current	0.0	0.0	0.0	121.9	121.9
+ Other Non-current Financial Liab	69.2	62.9	46.8	44.8	44.8
Non-current Financial Liabilities	69.2	62.9	46.8	166.7	166.7
+ Provisions — Non-current	106.2	109.5	124.3	152.9	152.9
+ Other Non-current Liabilities	0.0	0.0	0.0	180.2	180.2
Non-current Liabilities	175.4	172.4	171.1	499.8	499.8
+ Borrowings — Current	635.9	430.5	1,195.6	1,238.9	1,238.9
+ Trade Payables	679.8	735.6	879.9	835.1	835.1
+ Other Current Financial Liab	165.7	163.7	165.3	302.9	302.9
Current Financial Liabilities	1,481.3	1,329.8	2,240.7	2,376.9	2,376.9
+ Provisions — Current	70.1	65.3	85.9	111.2	111.2
+ Current Tax Liabilities	0.0	0.0	18.9	35.0	35.0
+ Other Current Liabilities	85.5	60.0	66.8	70.8	70.8
Current Liabilities	1,636.9	1,455.0	2,412.3	2,593.8	2,593.8
Total Liabilities	1,812.4	1,627.4	2,583.4	3,093.6	3,093.6
Total Equity & Liabilities	6,182.8	6,445.6	7,772.9	8,762.6	8,762.6
Assets — additional as-filed lines
+ Current Tax Assets	82.7	41.0	11.0	10.7	10.7
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	60.3	59.8	59.8
+ Dues to Other Creditors — Current	—	—	819.6	775.3	775.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.